Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells

The purpose of this study is to assess the human herpes virus reactivation 6 post autologous stem cells in 196 patients. The aim of our study was to describe the incidence of reactivation of HHV-6 in patients requiring autologous HSCT and determine the pathogenic role in this target population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hematologic Diseases Hemic and Lymphatic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Clermont-Ferrand, Clermont-Ferrand, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

all patients hospitalized in the Hematology Clinic of Saint-Etienne and Clermont-Ferrand and receiving autologous hematopoietic stem cells, according to the decision of the Consultative Meeting Multidisciplinary service;
Autologous recipients are included irrespective of causal hemopathy (myeloma, lymphoma, acute leukemia, mainly).

Exclusion criteria

The non-consenting patients or unable to give consent

Treatment and study plan

Primary outcomes

HHV-6 biological reactivation

Time frame: 40 days

HHV-6 biological reactivation (blood viral load) is defined by a detectable viral load HHV-6 and> 450 copies / mL on two occasions one week apart.

Secondary outcomes

Aplasia output or engraftment

Time frame: 40 days
Reconstitution of hematopoiesis

Time frame: 40 days
Disease HHV-6

Time frame: 40 days

Sponsors and collaborators

Lead sponsor

Institut de Cancérologie de la Loire

Other

Registry information

Official study title

Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells , Prospective, Open, Multicenter Study

Acronym: VIRAUTO6

Important dates

Study start: 2012
Primary completion: 2015
Study completion: 2015
First posted: Mar 18, 2014
Registry last updated: Sep 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed